News | June 03, 2021
Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
